Janux Therapeutics, Inc.
- Last sale
- Oct 16, 2026 · -4.62%
- Market cap
- $1.01B
- 61.17M shares
- Filings
- 443
Q3 2026−5.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−87.8% FY25 yoy
- $1.01B
- —
- 43.4×
- 1.1×
- -5.36%
- —
Twelve months to Sep 30, 2026 · derived
Price
Oct 16, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $10,000,000 | reported | |
| FY 2024 | 2024-12-31 | $10,588,000 | reported | |
| FY 2023 | 2023-12-31 | $8,083,000 | reported | |
| FY 2022 | 2022-12-31 | $8,612,000 | reported | |
| FY 2021 | 2021-12-31 | $3,637,000 | reported | |
| FY 2020 | 2020-12-31 | $0 | reported |
Pharmaceutical preparations
Janux Therapeutics, Inc. is the 169th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JAGXJaguar Health, Inc.$11.5M1.5%465.4%$2.0MCBIOCrescent Biopharma, Inc.$10.8M—1,419.6%$561.3M
JANXJanux Therapeutics, Inc. (this company)$10.0M5.6%1,136.3%$1.0B
ZBIOZenas BioPharma, Inc.$10.0M100.0%3,777.4%$1.9BPGENPrecigen, Inc.$9.7M146.7%2,588.2%$1.7BPRTAProthena Corp Public Ltd Co$9.7M92.8%2,520.6%$422.1MISCOInternational Stem Cell CORP$9.1M0.2%4.6%$2.6MBIOABioAge Labs, Inc.$9.0M—896.1%$260.1MROIVRoivant Sciences Ltd.$8.3M71.6%3,629.2%$29.0BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Janux Therapeutics, Inc. · CIK 1817713 · Engraved from SEC EDGAR